205:@0.890196:0.957873:0.915969:0.957873:0.915969:0.938882:0.890196:0.938882:0.008591:0.008591:0.008591
REFERENCES:@0.789358:0.066557:0.882352:0.066557:0.882352:0.045634:0.789358:0.045634:0.010295:0.008537:0.008058:0.008537:0.010295:0.008537:0.010706:0.010089:0.008398:0.009542
388. Winters, A. C. & Bernt, K. M. MLL-Rearranged Leukemias-An Update on Science and Clin-:@0.147059:0.119718:0.882353:0.119718:0.882353:0.101197:0.147059:0.101197:0.009483:0.009483:0.009483:0.004088:0.004814:0.018137:0.005105:0.010355:0.005644:0.008218:0.006931:0.006973:0.004088:0.003175:0.013572:0.004088:0.003175:0.013343:0.004088:0.003175:0.014298:0.003175:0.011891:0.008218:0.007097:0.010355:0.005852:0.004088:0.003175:0.013219:0.004088:0.003175:0.017826:0.004088:0.003175:0.017826:0.010563:0.010355:0.006848:0.012451:0.008446:0.008259:0.007097:0.007180:0.008259:0.010417:0.008778:0.008280:0.010355:0.003175:0.010749:0.008301:0.010500:0.009338:0.008218:0.016041:0.005271:0.008446:0.006973:0.006848:0.013572:0.010687:0.003175:0.013675:0.010457:0.010521:0.008010:0.005644:0.008218:0.003175:0.009857:0.010687:0.003175:0.009629:0.008176:0.005043:0.008218:0.010542:0.008176:0.008218:0.003175:0.008259:0.010542:0.010355:0.003175:0.013406:0.004773:0.005105:0.010691:0.006848
ical Approaches. Front Pediatr 5, 4 (2017).:@0.184412:0.140297:0.504462:0.140297:0.504462:0.121776:0.184412:0.121776:0.005043:0.008280:0.008550:0.004773:0.003735:0.012721:0.010044:0.010065:0.006765:0.010127:0.008446:0.007969:0.010272:0.008218:0.006973:0.004088:0.003735:0.009772:0.006765:0.009859:0.010355:0.005852:0.003735:0.010145:0.008280:0.010355:0.005271:0.008010:0.005852:0.007097:0.003735:0.009483:0.004088:0.003735:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
389. Pongers-Willemse, M. J. :@0.147059:0.160875:0.372502:0.160875:0.372502:0.142355:0.147059:0.142355:0.009483:0.009483:0.009483:0.004088:0.004814:0.010148:0.009857:0.010417:0.008778:0.008218:0.006931:0.006973:0.006848:0.018137:0.005229:0.004897:0.004711:0.008218:0.015916:0.007159:0.007948:0.004088:0.004387:0.017826:0.004088:0.004389:0.005105:0.004088:0.003735
et al.:@0.373155:0.160875:0.408951:0.160875:0.408951:0.142164:0.373155:0.142164:0.007346:0.005727:0.004482:0.009048:0.004607:0.004586
 Primers and protocols for standardized detection of minimal :@0.408954:0.160875:0.886088:0.160875:0.886088:0.142355:0.408954:0.142355:0.004389:0.010832:0.007097:0.005105:0.015896:0.008218:0.006931:0.006973:0.004387:0.008259:0.010542:0.010355:0.004389:0.010065:0.006765:0.009836:0.005644:0.010251:0.008176:0.009940:0.004773:0.006973:0.004389:0.005476:0.009859:0.007097:0.004387:0.006827:0.005956:0.008259:0.010542:0.010521:0.008259:0.006765:0.010355:0.005105:0.008031:0.008280:0.010355:0.004389:0.010293:0.008301:0.005644:0.008280:0.008278:0.005852:0.005043:0.009857:0.010687:0.004389:0.009857:0.005644:0.004389:0.016041:0.005105:0.010687:0.005105:0.015977:0.008550:0.004773:0.003735
residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor :@0.184412:0.181454:0.885999:0.181454:0.885999:0.162933:0.184412:0.162933:0.006765:0.008218:0.006910:0.005043:0.010044:0.010542:0.008550:0.004773:0.003673:0.010355:0.005105:0.007157:0.008446:0.008446:0.007159:0.008218:0.003673:0.005105:0.010687:0.003673:0.008446:0.008280:0.010065:0.005644:0.008218:0.003673:0.004711:0.008840:0.015709:0.010148:0.010272:0.009961:0.009919:0.004939:0.008446:0.006827:0.005852:0.005043:0.008176:0.003673:0.004711:0.008301:0.010500:0.009338:0.008218:0.016041:0.005269:0.008446:0.003673:0.010376:0.006910:0.005105:0.010417:0.008965:0.003673:0.005105:0.016041:0.015709:0.010376:0.010542:0.010044:0.009027:0.004711:0.009961:0.009816:0.010500:0.004773:0.005105:0.010687:0.003673:0.008259:0.010542:0.010355:0.003673:0.012140:0.003673:0.008176:0.008135:0.004897:0.004773:0.003673:0.006765:0.008278:0.008176:0.008301:0.010044:0.005644:0.009859:0.007097:0.003735
gene rearrangements and TAL1 deletions as PCR targets Report of the BIOMED-1 CON-:@0.184412:0.202033:0.882353:0.202033:0.882353:0.183512:0.184412:0.183512:0.008778:0.008218:0.010542:0.008218:0.004980:0.006765:0.008446:0.008259:0.007097:0.007180:0.008259:0.010417:0.008778:0.008218:0.015896:0.008218:0.010355:0.005852:0.006973:0.004980:0.008259:0.010542:0.010355:0.004980:0.010646:0.013572:0.010563:0.009483:0.004980:0.010293:0.008135:0.004711:0.008301:0.005852:0.005043:0.009857:0.010563:0.006973:0.004980:0.008446:0.006973:0.004980:0.011061:0.013343:0.012160:0.004980:0.005956:0.008259:0.006931:0.008778:0.008301:0.005852:0.006973:0.004980:0.012449:0.008301:0.010459:0.009857:0.007242:0.005852:0.004980:0.009857:0.005644:0.004980:0.006016:0.010274:0.008218:0.004980:0.011330:0.006205:0.014339:0.017826:0.010998:0.014671:0.006848:0.009483:0.004980:0.013406:0.014588:0.014821:0.006848
CERTED ACTION: Investigation of minimal residual disease in acute leukemia. Leukemia :@0.184412:0.222612:0.886142:0.222612:0.886142:0.204091:0.184412:0.204091:0.013343:0.010998:0.011642:0.012140:0.010998:0.014671:0.004067:0.012949:0.013343:0.012140:0.006205:0.014588:0.014754:0.004088:0.004067:0.006267:0.010334:0.008757:0.008218:0.006827:0.005852:0.005105:0.008965:0.008010:0.005852:0.005043:0.009857:0.010687:0.004067:0.009857:0.005644:0.004067:0.016041:0.005105:0.010687:0.005105:0.015977:0.008550:0.004773:0.004067:0.006765:0.008218:0.006912:0.005043:0.010042:0.010542:0.008550:0.004773:0.004067:0.010355:0.005105:0.007157:0.008446:0.008446:0.007159:0.008218:0.004067:0.005105:0.010687:0.004067:0.008446:0.008280:0.010065:0.005644:0.008218:0.004067:0.004713:0.008299:0.010500:0.009340:0.008218:0.016041:0.005269:0.008446:0.004088:0.004067:0.010747:0.008301:0.010500:0.009338:0.008218:0.016041:0.005271:0.008446:0.003735
13, 110–118 (1999).:@0.184412:0.243190:0.337206:0.243190:0.337206:0.224669:0.184412:0.224669:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
390. Cooper, M. D. & Alder, M. N. The Evolution of Adaptive Immune Systems. Cell vol. 124 :@0.147059:0.263769:0.886169:0.263769:0.886169:0.245248:0.147059:0.245248:0.009483:0.009483:0.009483:0.004088:0.004814:0.013634:0.010251:0.009836:0.010457:0.008218:0.005688:0.004088:0.005686:0.017826:0.004088:0.005686:0.013738:0.004088:0.005686:0.014298:0.005686:0.013696:0.004711:0.010293:0.008218:0.005686:0.004088:0.005686:0.017826:0.004088:0.005686:0.014754:0.004088:0.005686:0.010428:0.010280:0.008218:0.005686:0.010729:0.008757:0.009940:0.004462:0.010065:0.005852:0.005043:0.009857:0.010687:0.005686:0.009857:0.005644:0.005686:0.013032:0.010521:0.008010:0.010044:0.005852:0.005043:0.008757:0.008218:0.005686:0.006267:0.016041:0.015709:0.010376:0.010542:0.008218:0.005686:0.008923:0.008840:0.006827:0.005644:0.008218:0.015916:0.006973:0.004088:0.005686:0.013634:0.008135:0.004897:0.004773:0.005686:0.008759:0.009938:0.004526:0.004088:0.005686:0.009483:0.009483:0.009483:0.003735
815–822 (2006).:@0.184412:0.284348:0.310415:0.284348:0.310415:0.265827:0.184412:0.265827:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
391. Immunobiology: the immune system in health and disease. Choice Reviews Online vol. 32 :@0.147059:0.304926:0.886045:0.304926:0.886045:0.286406:0.147059:0.286406:0.009483:0.009483:0.009483:0.004088:0.004814:0.006267:0.016041:0.015709:0.010376:0.010542:0.009961:0.009836:0.005043:0.009940:0.004711:0.010044:0.009587:0.009255:0.004088:0.004358:0.006018:0.010272:0.008218:0.004358:0.005105:0.016041:0.015707:0.010376:0.010544:0.008218:0.004358:0.007056:0.008840:0.006827:0.005647:0.008218:0.016041:0.004358:0.005105:0.010687:0.004358:0.010272:0.008446:0.008550:0.004462:0.006018:0.010417:0.004358:0.008259:0.010542:0.010355:0.004358:0.010355:0.005105:0.007159:0.008444:0.008446:0.007159:0.007948:0.004088:0.004358:0.013406:0.010272:0.009857:0.005043:0.008176:0.008218:0.004358:0.012451:0.008487:0.008944:0.005043:0.008487:0.013385:0.006973:0.004358:0.014817:0.010791:0.004773:0.005105:0.010542:0.008218:0.004358:0.008757:0.009940:0.004524:0.004088:0.004358:0.009483:0.009483:0.003735
32–3876 (1995).:@0.184412:0.325505:0.310415:0.325505:0.310415:0.306984:0.184412:0.306984:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
392. Schatz, D. G. & Ji, Y. Recombination centres and the orchestration of V(D)J recombination. :@0.147059:0.346084:0.885985:0.346084:0.885985:0.327563:0.147059:0.327563:0.009483:0.009483:0.009483:0.004088:0.004814:0.009629:0.007969:0.010355:0.008010:0.005914:0.008031:0.004088:0.004171:0.013738:0.004088:0.004171:0.014256:0.004088:0.004171:0.014298:0.004171:0.005603:0.004856:0.004088:0.004171:0.009566:0.004088:0.004171:0.012451:0.008280:0.008176:0.009857:0.015813:0.009836:0.005105:0.010625:0.008010:0.005852:0.005043:0.009857:0.010687:0.004171:0.008176:0.008218:0.010355:0.005852:0.006765:0.008218:0.006973:0.004171:0.008259:0.010544:0.010355:0.004171:0.006018:0.010272:0.008218:0.004171:0.009857:0.006765:0.007969:0.010272:0.008218:0.006827:0.005852:0.007180:0.008010:0.005852:0.005043:0.009857:0.010687:0.004171:0.009857:0.005644:0.004171:0.013717:0.006308:0.014671:0.006308:0.006246:0.004171:0.006765:0.008280:0.008176:0.009857:0.015813:0.009836:0.005105:0.010625:0.008010:0.005852:0.005043:0.009857:0.010687:0.004088:0.003735
Nature Reviews Immunology vol. 11 251–263 (2011).:@0.184412:0.366663:0.594296:0.366663:0.594296:0.348142:0.184412:0.348142:0.014132:0.008010:0.005603:0.010376:0.006765:0.008218:0.003735:0.012451:0.008487:0.008944:0.005043:0.008487:0.013385:0.006973:0.003735:0.006265:0.016041:0.015709:0.010376:0.010542:0.009940:0.004711:0.010044:0.009587:0.008840:0.003735:0.008757:0.009940:0.004524:0.004088:0.003735:0.009483:0.009483:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
393. Roth, D. B. V(D)J Recombination: Mechanism, Errors, and Fidelity. Mobile DNA III 311–:@0.147059:0.387241:0.882285:0.387241:0.882285:0.368720:0.147059:0.368720:0.009483:0.009483:0.009483:0.004088:0.004814:0.012451:0.009836:0.006018:0.010417:0.004088:0.004814:0.013738:0.004088:0.004814:0.010957:0.004088:0.004814:0.013717:0.006308:0.014671:0.006308:0.006246:0.004814:0.012451:0.008280:0.008176:0.009857:0.015813:0.009836:0.005105:0.010625:0.008010:0.005852:0.005043:0.009857:0.010687:0.004088:0.004814:0.017243:0.008280:0.007969:0.010355:0.008261:0.010687:0.005105:0.006908:0.016041:0.004088:0.004814:0.010998:0.007097:0.006765:0.009857:0.006931:0.006973:0.004088:0.004814:0.008259:0.010542:0.010355:0.004814:0.010355:0.005041:0.010295:0.008135:0.004773:0.004792:0.005852:0.007263:0.004088:0.004814:0.017245:0.009961:0.009836:0.005229:0.004711:0.008218:0.004814:0.014339:0.014007:0.013572:0.004814:0.006599:0.006599:0.006599:0.004814:0.009483:0.009483:0.009483:0.010729
324 (2015).:@0.184412:0.407820:0.271236:0.407820:0.271236:0.389299:0.184412:0.389299:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
394. Jeske, D. J., Jarvis, J., Milstein, C. & Capra, J. D. Junctional diversity is essential to antibody :@0.147059:0.428399:0.886086:0.428399:0.886086:0.409878:0.147059:0.409878:0.009483:0.009483:0.009483:0.004088:0.004814:0.005665:0.008218:0.006869:0.009338:0.007948:0.004088:0.004949:0.013738:0.004088:0.004949:0.005105:0.004088:0.004088:0.004949:0.005561:0.008259:0.007637:0.008944:0.005105:0.006973:0.004088:0.004949:0.005105:0.004088:0.004088:0.004949:0.017660:0.005229:0.004773:0.006827:0.005644:0.008218:0.005105:0.010687:0.004088:0.004949:0.013343:0.004088:0.004949:0.014298:0.004949:0.013613:0.008010:0.010065:0.007180:0.008446:0.004088:0.004949:0.005105:0.004088:0.004949:0.013738:0.004088:0.004949:0.005561:0.010376:0.010542:0.008280:0.005852:0.005043:0.009857:0.010625:0.008550:0.004773:0.004949:0.010355:0.005043:0.008757:0.008218:0.006931:0.006910:0.004794:0.005852:0.008840:0.004949:0.005105:0.006973:0.004949:0.008218:0.006848:0.007159:0.008218:0.010355:0.005852:0.005271:0.008550:0.004773:0.004949:0.005644:0.010044:0.004949:0.008259:0.010355:0.005852:0.005043:0.010231:0.010251:0.010293:0.008840:0.003735
activity. J. Immunol. 133, 1090–1092 (1984).:@0.184412:0.448977:0.522103:0.448977:0.522103:0.430456:0.184412:0.430456:0.008446:0.008280:0.005852:0.005043:0.008944:0.004794:0.005852:0.007263:0.004088:0.003735:0.005105:0.004088:0.003735:0.006265:0.016041:0.015709:0.010376:0.010544:0.009940:0.004524:0.004088:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
395. Szczepański, T. :@0.147059:0.469556:0.302903:0.469556:0.302903:0.451035:0.147059:0.451035:0.009483:0.009483:0.009483:0.004088:0.004814:0.009193:0.008031:0.008176:0.008031:0.008301:0.010334:0.008259:0.005344:0.005219:0.006869:0.009733:0.004856:0.004088:0.004275:0.009961:0.004088:0.003735
et al.:@0.303441:0.469556:0.339123:0.469556:0.339123:0.450844:0.303441:0.450844:0.007346:0.005727:0.004368:0.009048:0.004607:0.004586
 Comparative analysis of Ig and TCR gene rearrangements at diagnosis :@0.339123:0.469556:0.886098:0.469556:0.886098:0.451035:0.339123:0.451035:0.004275:0.013634:0.009857:0.015709:0.010334:0.008259:0.007178:0.008012:0.005852:0.005043:0.008757:0.008218:0.004275:0.008259:0.010625:0.008550:0.004711:0.008840:0.006910:0.005105:0.006973:0.004275:0.009857:0.005644:0.004275:0.005893:0.008965:0.004275:0.008259:0.010544:0.010355:0.004275:0.011870:0.013343:0.012160:0.004275:0.008778:0.008218:0.010542:0.008218:0.004275:0.006765:0.008446:0.008259:0.007097:0.007180:0.008259:0.010417:0.008780:0.008218:0.015896:0.008218:0.010355:0.005852:0.006973:0.004275:0.008010:0.005852:0.004275:0.010355:0.005271:0.008363:0.008965:0.010542:0.009961:0.006910:0.005105:0.006973:0.003735
and at relapse of childhood precursor-B–ALL provides improved strategies for selection of :@0.184412:0.490135:0.886001:0.490135:0.886001:0.471614:0.184412:0.471614:0.008259:0.010542:0.010355:0.004545:0.008010:0.005852:0.004545:0.006765:0.008135:0.004939:0.008010:0.010168:0.007159:0.008218:0.004545:0.009857:0.005644:0.004545:0.007969:0.010417:0.005229:0.004711:0.010480:0.010272:0.010251:0.010251:0.010355:0.004545:0.010065:0.006765:0.008280:0.008280:0.010376:0.006931:0.007159:0.009857:0.006578:0.006848:0.011496:0.010729:0.013572:0.010563:0.010563:0.004545:0.010065:0.006765:0.009878:0.008944:0.005043:0.010293:0.008218:0.006973:0.004545:0.005105:0.015709:0.010065:0.006765:0.009878:0.008757:0.008280:0.010355:0.004545:0.006827:0.005852:0.007178:0.008012:0.005644:0.008218:0.008965:0.005041:0.008218:0.006973:0.004545:0.005478:0.009857:0.007097:0.004545:0.007159:0.008135:0.004711:0.008280:0.008280:0.005852:0.005043:0.009857:0.010687:0.004545:0.009857:0.005644:0.003735
stable PCR targets for monitoring of minimal residual disease. Blood 99, 2315–2323 (2002).:@0.184412:0.510713:0.882432:0.510713:0.882432:0.492193:0.184412:0.492193:0.006827:0.005956:0.008280:0.009919:0.004711:0.008218:0.003611:0.011061:0.013343:0.012160:0.003611:0.005956:0.008259:0.006931:0.008778:0.008301:0.005852:0.006973:0.003611:0.005478:0.009857:0.007097:0.003611:0.015896:0.009857:0.010687:0.004794:0.005644:0.009857:0.007097:0.005105:0.010417:0.008965:0.003611:0.009857:0.005644:0.003611:0.016041:0.005105:0.010687:0.005105:0.015979:0.008550:0.004773:0.003611:0.006765:0.008218:0.006910:0.005043:0.010044:0.010542:0.008548:0.004773:0.003611:0.010355:0.005105:0.007159:0.008446:0.008446:0.007159:0.007948:0.004088:0.003611:0.011268:0.004711:0.010251:0.010251:0.010355:0.003611:0.009483:0.009483:0.004088:0.003611:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003611:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
396. van Dongen, J. J. M., van der Velden, V. H. J., Brüggemann, M. & Orfao, A. Minimal residual :@0.147059:0.531292:0.886219:0.531292:0.886219:0.512771:0.147059:0.512771:0.009483:0.009483:0.009483:0.004088:0.004814:0.008944:0.008259:0.010687:0.003756:0.014754:0.009857:0.010417:0.008778:0.008218:0.010687:0.004088:0.003756:0.005105:0.004088:0.003756:0.005105:0.004088:0.003756:0.017826:0.004088:0.004088:0.003756:0.008944:0.008259:0.010687:0.003756:0.010293:0.008218:0.007097:0.003756:0.011579:0.008135:0.004711:0.010293:0.008218:0.010687:0.004088:0.003756:0.010438:0.004088:0.003746:0.015315:0.004088:0.003756:0.005105:0.004088:0.004088:0.003756:0.011351:0.007242:0.010376:0.009068:0.008778:0.008218:0.015979:0.008259:0.010687:0.010687:0.004088:0.003756:0.017826:0.004088:0.003756:0.014298:0.003756:0.014817:0.007097:0.005644:0.008446:0.009336:0.004088:0.003756:0.013572:0.004088:0.003756:0.017660:0.005105:0.010687:0.005105:0.015979:0.008550:0.004773:0.003756:0.006765:0.008218:0.006910:0.005043:0.010044:0.010542:0.008550:0.004773:0.003735
disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standard-:@0.184412:0.551871:0.882353:0.551871:0.882353:0.533350:0.184412:0.533350:0.010355:0.005105:0.007159:0.008446:0.008446:0.007157:0.008218:0.004814:0.010355:0.005271:0.008363:0.008965:0.010542:0.009961:0.006827:0.005852:0.005043:0.008176:0.006973:0.004814:0.005105:0.010687:0.004814:0.008446:0.008280:0.010065:0.005644:0.008218:0.004814:0.004711:0.008840:0.015709:0.010148:0.010272:0.009961:0.009919:0.004939:0.008446:0.006827:0.005852:0.005043:0.008176:0.004814:0.004711:0.008301:0.010500:0.009338:0.008218:0.016041:0.005271:0.008446:0.004088:0.004814:0.010542:0.008280:0.008280:0.010355:0.004814:0.005478:0.009857:0.007097:0.004814:0.007159:0.008218:0.010563:0.006910:0.004794:0.005852:0.005043:0.008757:0.007948:0.004088:0.004814:0.005644:0.008446:0.006827:0.005852:0.004088:0.004814:0.008259:0.010542:0.010355:0.004814:0.006829:0.005954:0.008261:0.010542:0.010521:0.008259:0.006765:0.010357:0.006848
ized technologies. Blood 125, 3996–4009 (2015).:@0.184412:0.572450:0.556299:0.572450:0.556299:0.553929:0.184412:0.553929:0.005105:0.008031:0.008280:0.010355:0.003735:0.005644:0.008278:0.007971:0.010417:0.010542:0.009940:0.004711:0.010044:0.008965:0.005043:0.008218:0.006973:0.004088:0.003735:0.011266:0.004711:0.010251:0.010251:0.010355:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
397. van Dongen, J. J. :@0.147059:0.593028:0.314919:0.593028:0.314919:0.574507:0.147059:0.574507:0.009483:0.009483:0.009483:0.004088:0.004814:0.008944:0.008259:0.010687:0.004565:0.014754:0.009857:0.010417:0.008778:0.008218:0.010687:0.004088:0.004565:0.005105:0.004088:0.004565:0.005105:0.004088:0.003735
et al.:@0.315763:0.593028:0.351746:0.593028:0.351746:0.574316:0.315763:0.574316:0.007346:0.005727:0.004669:0.009048:0.004607:0.004586
 Standardized RT-PCR analysis of fusion gene transcripts from chro-:@0.351746:0.593028:0.882353:0.593028:0.882353:0.574507:0.351746:0.574507:0.004565:0.008902:0.005956:0.008259:0.010542:0.010521:0.008259:0.006765:0.010355:0.005105:0.008031:0.008280:0.010355:0.004565:0.011642:0.010729:0.006848:0.011061:0.013343:0.012160:0.004565:0.008259:0.010625:0.008550:0.004711:0.008840:0.006910:0.005105:0.006973:0.004565:0.009857:0.005644:0.004565:0.005790:0.010376:0.006910:0.005043:0.009857:0.010687:0.004565:0.008778:0.008218:0.010542:0.008218:0.004565:0.005852:0.007180:0.008259:0.010563:0.007157:0.008176:0.007097:0.004794:0.010044:0.005852:0.006973:0.004565:0.005831:0.006765:0.009857:0.016041:0.004565:0.007969:0.010417:0.006765:0.010075:0.006848
mosome aberrations in acute leukemia for detection of minimal residual disease. Report of :@0.184412:0.613607:0.886124:0.613607:0.886124:0.595086:0.184412:0.595086:0.015896:0.009961:0.007159:0.009857:0.015896:0.008218:0.004233:0.008280:0.010228:0.008218:0.007097:0.007180:0.008010:0.005852:0.005043:0.009857:0.010563:0.006973:0.004233:0.005105:0.010687:0.004233:0.008446:0.008280:0.010065:0.005644:0.008218:0.004233:0.004711:0.008301:0.010500:0.009338:0.008218:0.016041:0.005271:0.008446:0.004233:0.005478:0.009857:0.007097:0.004233:0.010293:0.008301:0.005644:0.008280:0.008280:0.005852:0.005043:0.009857:0.010687:0.004233:0.009857:0.005644:0.004233:0.016041:0.005105:0.010687:0.005105:0.015979:0.008548:0.004773:0.004233:0.006765:0.008218:0.006910:0.005043:0.010044:0.010542:0.008550:0.004773:0.004233:0.010355:0.005105:0.007159:0.008446:0.008446:0.007159:0.007948:0.004088:0.004233:0.012451:0.008301:0.010459:0.009857:0.007242:0.005852:0.004233:0.009857:0.005644:0.003735
the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leuke-:@0.184412:0.634186:0.882353:0.634186:0.882353:0.615665:0.184412:0.615665:0.006018:0.010272:0.008218:0.003860:0.011330:0.006205:0.014339:0.017826:0.010998:0.014671:0.006848:0.009483:0.003860:0.013634:0.009857:0.010542:0.008176:0.008218:0.007242:0.005644:0.008278:0.010355:0.003860:0.013034:0.008278:0.005852:0.005043:0.009857:0.010687:0.004088:0.003860:0.005105:0.010332:0.008759:0.008218:0.006827:0.005852:0.005105:0.008965:0.008008:0.005852:0.005043:0.009857:0.010687:0.003860:0.009857:0.005644:0.003860:0.016041:0.005105:0.010687:0.005105:0.015977:0.008550:0.004773:0.003860:0.006765:0.008218:0.006910:0.005043:0.010044:0.010542:0.008548:0.004773:0.003860:0.010355:0.005105:0.007157:0.008446:0.008446:0.007159:0.008218:0.003860:0.005105:0.010687:0.003860:0.008446:0.008280:0.010065:0.005644:0.008218:0.003860:0.004711:0.008301:0.010500:0.009338:0.008271:0.006848
mia. Leukemia 13, 1901–1928 (1999).:@0.184412:0.654764:0.474351:0.654764:0.474351:0.636244:0.184412:0.636244:0.016041:0.005271:0.008446:0.004088:0.003735:0.010747:0.008301:0.010500:0.009338:0.008218:0.016041:0.005271:0.008446:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
398. van der Velden, V. H. J. :@0.147059:0.675343:0.358310:0.675343:0.358310:0.656822:0.147059:0.656822:0.009483:0.009483:0.009483:0.004088:0.004814:0.008944:0.008259:0.010687:0.003165:0.010293:0.008218:0.007097:0.003175:0.011579:0.008135:0.004711:0.010293:0.008218:0.010687:0.004088:0.003165:0.010438:0.004088:0.003165:0.015315:0.004088:0.003165:0.005105:0.004088:0.003735
et al.:@0.357733:0.675343:0.392284:0.675343:0.392284:0.656631:0.357733:0.656631:0.007346:0.005727:0.003237:0.009048:0.004607:0.004586
 Detection of minimal residual disease in hematologic malignan-:@0.392282:0.675343:0.882353:0.675343:0.882353:0.656822:0.392282:0.656822:0.003165:0.014754:0.008301:0.005644:0.008280:0.008280:0.005852:0.005043:0.009857:0.010687:0.003165:0.009857:0.005644:0.003165:0.016041:0.005105:0.010687:0.005105:0.015979:0.008550:0.004773:0.003165:0.006765:0.008218:0.006910:0.005043:0.010044:0.010542:0.008550:0.004773:0.003165:0.010355:0.005105:0.007159:0.008444:0.008446:0.007159:0.008218:0.003175:0.005105:0.010687:0.003165:0.010272:0.008218:0.015979:0.008010:0.005644:0.009940:0.004711:0.010044:0.008965:0.005043:0.008176:0.003165:0.015979:0.008550:0.004773:0.005105:0.008965:0.010625:0.008259:0.010680:0.006848
cies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia :@0.184412:0.695922:0.886061:0.695922:0.886061:0.677401:0.184412:0.677401:0.008176:0.005043:0.008218:0.006973:0.003175:0.009857:0.008840:0.003175:0.006765:0.008446:0.008550:0.004773:0.006848:0.005852:0.005105:0.015896:0.008218:0.003175:0.009733:0.010542:0.008259:0.010355:0.005852:0.004794:0.005956:0.008010:0.005852:0.005043:0.008757:0.008218:0.003175:0.011061:0.013343:0.012160:0.004088:0.003175:0.010065:0.007097:0.005105:0.010542:0.008176:0.004794:0.010148:0.004711:0.008218:0.006973:0.004088:0.003175:0.008010:0.010044:0.010065:0.006765:0.010127:0.008446:0.007969:0.010272:0.008218:0.006973:0.004088:0.003175:0.008261:0.010542:0.010355:0.003175:0.004939:0.008280:0.010228:0.009859:0.007178:0.008010:0.005647:0.009857:0.007635:0.008840:0.003175:0.008446:0.006827:0.010459:0.008280:0.008278:0.005852:0.006973:0.004088:0.003175:0.010747:0.008301:0.010500:0.009338:0.008218:0.016041:0.005271:0.008446:0.003735
17, 1013–1034 (2003).:@0.184412:0.716500:0.356173:0.716500:0.356173:0.697980:0.184412:0.697980:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
399. Sánchez, R., Ayala, R. & Martínez-López, J. Minimal Residual Disease Monitoring with :@0.147059:0.737079:0.886101:0.737079:0.886101:0.718558:0.147059:0.718558:0.009483:0.009483:0.009483:0.004088:0.004814:0.009193:0.008259:0.010542:0.007969:0.010272:0.008487:0.008031:0.004088:0.006931:0.012451:0.004088:0.004088:0.006931:0.012223:0.008840:0.008550:0.004937:0.008446:0.004088:0.006931:0.012451:0.004088:0.006931:0.014298:0.006931:0.017348:0.008259:0.007240:0.005852:0.005105:0.010542:0.008487:0.008031:0.006848:0.010749:0.009836:0.010457:0.008487:0.008031:0.004088:0.006931:0.005105:0.004088:0.006931:0.017660:0.005105:0.010687:0.005105:0.015979:0.008550:0.004773:0.006931:0.012451:0.008218:0.006910:0.005043:0.010044:0.010542:0.008550:0.004773:0.006931:0.014568:0.005105:0.007159:0.008446:0.008446:0.007159:0.008218:0.006931:0.017245:0.009857:0.010687:0.004794:0.005644:0.009857:0.007097:0.005105:0.010417:0.008965:0.006931:0.013385:0.004794:0.006018:0.010417:0.003735
Next-Generation Sequencing Methodologies in Hematological Malignancies. Int. J. Mol. :@0.184412:0.757658:0.886065:0.757658:0.886065:0.739137:0.184412:0.739137:0.014111:0.008280:0.009172:0.005852:0.006848:0.014381:0.008218:0.010542:0.008218:0.007178:0.008012:0.005852:0.005043:0.009857:0.010687:0.006641:0.009629:0.008280:0.009733:0.010314:0.008218:0.010542:0.008176:0.005105:0.010417:0.008965:0.006641:0.017245:0.008301:0.006018:0.010272:0.010251:0.010293:0.009940:0.004711:0.010044:0.008965:0.005043:0.008218:0.006973:0.006641:0.005105:0.010687:0.006641:0.014734:0.008218:0.015979:0.008010:0.005644:0.009940:0.004711:0.010044:0.008965:0.005043:0.008280:0.008550:0.004773:0.006641:0.017348:0.008550:0.004773:0.005105:0.008965:0.010625:0.008259:0.010542:0.008176:0.005043:0.008218:0.006973:0.004088:0.006641:0.006267:0.010355:0.005852:0.004088:0.006641:0.005105:0.004088:0.006641:0.017245:0.009940:0.004524:0.004088:0.003735
Sci. 20, (2019).:@0.184412:0.778237:0.296325:0.778237:0.296325:0.759716:0.184412:0.759716:0.009629:0.008176:0.004856:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
400. Leukemia and Lymphoma Society (LLS): Minimal residual disease.  https://www.lls.org/:@0.147059:0.798815:0.882353:0.798815:0.882353:0.780294:0.147059:0.780294:0.009483:0.009483:0.009483:0.004088:0.004814:0.010749:0.008301:0.010500:0.009338:0.008218:0.016041:0.005269:0.008446:0.007554:0.008259:0.010542:0.010355:0.007554:0.009650:0.008840:0.015709:0.010148:0.010272:0.009857:0.015979:0.008446:0.007554:0.009629:0.010249:0.008176:0.005045:0.008299:0.005852:0.008840:0.007554:0.006308:0.010563:0.010563:0.009193:0.006308:0.004088:0.007554:0.017660:0.005105:0.010687:0.005105:0.015977:0.008550:0.004773:0.007554:0.006765:0.008218:0.006910:0.005043:0.010044:0.010542:0.008550:0.004773:0.007554:0.010355:0.005105:0.007159:0.008446:0.008446:0.007157:0.007948:0.004088:0.003735:0.003872:0.010085:0.005603:0.005603:0.010168:0.006973:0.004088:0.006454:0.006454:0.013883:0.013881:0.011808:0.004088:0.004897:0.004773:0.006973:0.004088:0.009857:0.006931:0.008965:0.006454
sites/default/files/National/USA/Pdf/Publications/FS35_MRD_Final_2019.pdf.:@0.184412:0.819394:0.797220:0.819394:0.797220:0.800873:0.184412:0.800873:0.006910:0.004794:0.005644:0.008218:0.006973:0.006454:0.010293:0.008218:0.005644:0.008010:0.010500:0.004462:0.005852:0.006454:0.005167:0.005290:0.004711:0.008218:0.006973:0.006454:0.014132:0.008010:0.005852:0.005043:0.009857:0.010625:0.008550:0.004773:0.006454:0.014568:0.009193:0.013572:0.006454:0.010148:0.010355:0.005644:0.006454:0.010893:0.010314:0.009919:0.004773:0.005043:0.008280:0.008010:0.005852:0.005043:0.009857:0.010563:0.006973:0.006454:0.010251:0.009193:0.009483:0.009483:0.010376:0.017826:0.012160:0.014671:0.010376:0.010353:0.005105:0.010625:0.008550:0.004773:0.010376:0.009483:0.009483:0.009483:0.009483:0.004088:0.010457:0.010355:0.005396:0.004088
401. Mason, J. & Griffiths, M. Detection of Minimal Residual Disease in Leukaemia by RT-PCR. :@0.147059:0.839973:0.886117:0.839973:0.886117:0.821452:0.147059:0.821452:0.009483:0.009483:0.009483:0.004088:0.004814:0.017348:0.008446:0.007159:0.009857:0.010687:0.004088:0.003860:0.005105:0.004088:0.003860:0.014298:0.003860:0.014070:0.007097:0.005105:0.005174:0.005174:0.004863:0.006018:0.010293:0.006973:0.004088:0.003860:0.017826:0.004088:0.003860:0.014752:0.008301:0.005644:0.008280:0.008280:0.005852:0.005043:0.009857:0.010687:0.003860:0.009857:0.005644:0.003860:0.017660:0.005105:0.010687:0.005105:0.015979:0.008548:0.004773:0.003860:0.012451:0.008218:0.006910:0.005043:0.010044:0.010542:0.008550:0.004773:0.003860:0.014568:0.005105:0.007157:0.008446:0.008446:0.007159:0.008218:0.003860:0.005105:0.010687:0.003860:0.010749:0.008299:0.010500:0.009650:0.008446:0.008218:0.016041:0.005271:0.008446:0.003860:0.009857:0.008840:0.003860:0.011642:0.010729:0.006848:0.011061:0.013343:0.012449:0.004088:0.003735
Methods in Molecular Biology 269–280 (2011) doi:10.1007/978-1-60761-947-5_18.:@0.184412:0.860551:0.829856:0.860551:0.829856:0.842031:0.184412:0.842031:0.017245:0.008301:0.006018:0.010272:0.010251:0.010355:0.006973:0.003735:0.005105:0.010687:0.003735:0.017243:0.009940:0.004711:0.008280:0.008280:0.010500:0.004939:0.008259:0.007097:0.003735:0.011351:0.005043:0.009940:0.004711:0.010044:0.009587:0.008840:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.003731:0.010293:0.009857:0.005105:0.004088:0.009483:0.009483:0.004088:0.009483:0.009483:0.009483:0.009483:0.006454:0.009483:0.009483:0.009483:0.006848:0.009483:0.006848:0.009483:0.009483:0.009483:0.009483:0.009483:0.006848:0.009483:0.009483:0.009483:0.006848:0.009483:0.010376:0.009483:0.009475:0.004088
402. Ozsolak, F. & Milos, P. M. RNA sequencing: advances, challenges and opportunities. Nat. :@0.147059:0.881130:0.886065:0.881130:0.886065:0.862609:0.147059:0.862609:0.009483:0.009483:0.009483:0.004088:0.004814:0.014920:0.008031:0.007159:0.009940:0.004939:0.008550:0.009566:0.004088:0.005644:0.007904:0.004088:0.005644:0.014298:0.005644:0.017660:0.005227:0.004711:0.009961:0.006973:0.004088:0.005644:0.008010:0.004088:0.005644:0.017826:0.004088:0.005644:0.012160:0.014009:0.013572:0.005644:0.007159:0.008280:0.009733:0.010314:0.008218:0.010542:0.008176:0.005105:0.010417:0.008965:0.004088:0.005644:0.008446:0.010293:0.008944:0.008259:0.010544:0.008176:0.008218:0.006973:0.004088:0.005644:0.007971:0.010353:0.008550:0.004897:0.004711:0.008218:0.010417:0.008780:0.008218:0.006973:0.005644:0.008259:0.010542:0.010355:0.005644:0.009836:0.010044:0.010459:0.009857:0.007240:0.005605:0.010376:0.010687:0.004794:0.005852:0.005041:0.008218:0.006973:0.004088:0.005644:0.014132:0.008010:0.005852:0.004088:0.003735
Rev. Genet. 12, 87–98 (2011).:@0.184412:0.901709:0.409484:0.901709:0.409484:0.883188:0.184412:0.883188:0.012451:0.008487:0.007367:0.004088:0.003735:0.014381:0.008218:0.010542:0.008301:0.005852:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.010729:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088